EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel strategies to reverse chemoresistance in colorectal cancer

Shu-Chang Ma iD, Jia-Qi Zhang, Tian-Hua Yan, Ming-Xing Miao, Ye-Min Cao, Yong-Bing Cao, Li-Chao Zhang, Ling Li

Cancer Medicine · 2023-05 · 12 (10) · 11073-11096

DOI: 10.1002/cam4.5594 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 16.01.2023. Verfasst von Shu-Chang Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: MicroRNAs, Colorectal Neoplasms. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a common gastrointestinal malignancy with high morbidity and fatality. Chemotherapy, as traditional therapy for CRC, has exerted well antitumor effect and greatly improved the survival of CRC patients. Nevertheless, chemoresistance is one of the major problems during chemotherapy for CRC and significantly limits the efficacy of the treatment and influences the prognosis of patients. To overcome chemoresistance in CRC, many strategies are being investigated. Here, we review the common and novel measures to combat the resistance, including drug repurposing (nonsteroidal anti‐inflammatory drugs, metformin, dichloroacetate, enalapril, ivermectin, bazedoxifene, melatonin, and S‐adenosylmethionine), gene therapy (ribozymes, RNAi, CRISPR/Cas9, epigenetic therapy, antisense oligonucleotides, and noncoding RNAs), protein inhibitor (EFGR inhibitor, S1PR2 inhibitor, and DNA methyltransferase inhibitor), natural herbal compounds (polyphenols, terpenoids, quinones, alkaloids, and sterols), new drug delivery system (nanocarriers, liposomes, exosomes, and hydrogels), and combination therapy. These common or novel strategies for the reversal of chemoresistance promise to improve the treatment of CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsColorectal NeoplasmsHumansDrug Resistance, NeoplasmRNA InterferencePrognosisCell Line, Tumor

Stichwörter der Autor:innen

chemoresistancecolorectal cancernovel strategiesreversal of resistance

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Institute of Vascular Disease, Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • Department of Physiology and Pharmacology, China Pharmaceutic University, Nanjing, China.
  • Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China.

ORCID-Profile: Shu-Chang Ma

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Ma, S. C., Zhang, J. Q., Yan, T. H., Miao, M. X., Cao, Y. M., Cao, Y. B., Zhang, L. C., & Li, L. (2023). Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Medicine, 12(10), 11073-11096. https://doi.org/10.1002/cam4.5594

Vancouver

Ma SC, Zhang JQ, Yan TH, Miao MX, Cao YM, Cao YB, et al. Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Medicine. 2023;12(10):11073-11096. doi:10.1002/cam4.5594

BibTeX
@article{Ma2023,
  author = {Ma, Shu-Chang and Zhang, Jia-Qi and Yan, Tian-Hua and Miao, Ming-Xing and Cao, Ye-Min and Cao, Yong-Bing and Zhang, Li-Chao and Li, Ling},
  title = {Novel strategies to reverse chemoresistance in colorectal cancer},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {10},
  pages = {11073--11096},
  doi = {10.1002/cam4.5594}
}
Kostenlos starten →